Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase

Elke Weißhaar(Heidelberg University), Sonja Ständer(University Hospital Münster), Gil Yosipovitch(University of Miami), Adam Reich(University of Rzeszów), Howard Hait(Trevi Therapeutics (United States)), Franz J. Legat(Medical University of Graz), Jacek C. Szepietowski(Wroclaw Medical University), Claudia Zeidler(University Hospital Münster), Birgit Sadoghi(Medical University of Graz), Leigh Nattkemper(Temple University), JD Bernhard(University of Massachusetts Chan Medical School), Thomas Sciascia(Trevi Therapeutics (United States))
Journal of the European Academy of Dermatology and Venereology
November 15, 2021
10.1111/jdv.17816
Cited by 48

Related Papers

The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
|The Lancet|2015|566
Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions
|Acta Dermato Venereologica|2019|189
European Surveillance System on Contact Allergies (<scp>ESSCA</scp>): results with the European baseline series, 2013/14
|Journal of the European Academy of Dermatology and Venereology|2017|124